clinicalomicsprowebdirectory
Facebook
Linkedin
Twitter
News
Topics
Informatics
Molecular Dx
Patient Care
Oncology
Precision Medicine
Translational Research
Magazine
Browse Issues
Subscribe
Marketplace
Translational Research
Molecular Diagnostics
Oncology/Therapeutics
Healthcare Informatics
Subscribe
Get Inside Precision Medicine Magazine
Get Inside Precision Medicine eNewsletters
Multimedia
eBooks
Webinars
Summits
Learning Labs
Podcasts
Inside Precision Medicine Live
Search
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Privacy Policy
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Inside Precision Medicine
News
News & Features
Timberlyne Therapeutics Launched Last Week with a $180 Million Series A…
News & Features
New Insights into T-Cell Role in Viral Defense Could Transform Vaccine…
Molecular Dx
Sensitive Tumor DNA Test Effective at Predicting Lung Cancer Progression
Informatics
JPM 2025: NVIDIA, Mayo Clinic Partner on AI-Powered Digital Pathology
News & Features
FDA Clears Solid Biosciences Neurodegeneration Gene Therapy IND
Topics
Informatics
Molecular Dx
Patient Care
Oncology
Precision Medicine
Translational Research
Magazine
Browse Issues
Subscribe
Marketplace
Translational Research
Molecular Diagnostics
Oncology/Therapeutics
Healthcare Informatics
Subscribe
Get Inside Precision Medicine Magazine
Get Inside Precision Medicine eNewsletters
Multimedia
eBooks
Webinars
Summits
Learning Labs
Podcasts
Inside Precision Medicine Live
Inside Precision Medicine
Firepower and Focus: OncoCyte Launches NSCLC Stratification, Broadens Dx Offerings
AstraZeneca
Molecular Dx
Firepower and Focus: OncoCyte Launches NSCLC Stratification, Broadens Dx Offerings
January 24, 2020
0
Molecular Dx
FDA Approves Myriad BRACAnalysis CDx for Lynparza in Metastatic Pancreatic Cancer
December 30, 2019
0
Molecular Dx
Myriad to Pursue mCRPC Approval for BRACAnalysis CDx
August 7, 2019
0
Molecular Dx
FoundationOne CDx Approved as Companion Diagnostic to Lynparza in Ovarian Cancer
July 3, 2019
0
Molecular Dx
Owlstone Medical to Collaborate on Breath-Based Pulmonary Hypertension Test
May 21, 2019
0
Molecular Dx
Myriad Genetics Expands CDx Collaboration with AstraZeneca, Merck & Co.
April 4, 2019
0
News & Features
AstraZeneca, Cancer Research UK Partner on Functional Genomics Center
December 10, 2018
0
Molecular Dx
mRNA Therapy Developer Moderna Raises $604M in Largest-Ever Biotech IPO
December 7, 2018
0
News & Features
AstraZeneca to ID Asthma, COPD Biomarkers Using Owlstone Medical’s Breath Biopsy
April 9, 2018
0
Molecular Dx
Myriad’s BRACAnalysis Gets Pre-Market Approval in Japan as Lynparza CDx
April 2, 2018
0
1
...
6
7
8
9
Page 7 of 9
Related Content
Sensitive Tumor DNA Test Effective at Predicting Lung Cancer Progression
Tongue Cancer Organoids Reveal Key Pathways for Overcoming Drug Resistance
New Test Predicts Survival in Early-Stage Lung Cancer Better than Current Methods
Topical Therapy Trains Immune System to Eliminate Precancerous Skin Lesions
Inside Precision Medicine
![Messenger RNA (mRNA) therapy developer Moderna has raised at least $604.3 million in gross proceeds in the largest initial public offering for a biotech. [© Argus/Fotolia]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/2040.jpeg "mRNA Therapy Developer Moderna Raises $604M in Largest-Ever Biotech IPO")
![Owlstone Medical's Breath Biospsy platform services will be used by AstraZeneca to identify novel biomarkers differentiating between disease phenotypes for asthma and COPD. [Owlstone Medical]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/1594.jpeg "AstraZeneca to ID Asthma, COPD Biomarkers Using Owlstone Medical’s Breath Biopsy")
